Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1992
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2003 1
2004 1
2020 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Novel biomarkers for the management of chronic hepatitis B.
Inoue T, Tanaka Y. Inoue T, et al. Clin Mol Hepatol. 2020 Jul;26(3):261-279. doi: 10.3350/cmh.2020.0032. Epub 2020 Jun 15. Clin Mol Hepatol. 2020. PMID: 32536045 Free PMC article. Review.
In CHB patients with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is significantly associated with hopeful outcomes. Therefore, HBcrAg can predict HCC occurrence or recurrence. ...Because alpha fetoprotein (AFP …
In CHB patients with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is s …
Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies.
Li X, Wan X, Liu J, Wang H, Li A, Ke C, Tang S, Zhao W, Cai S, Wan C. Li X, et al. Microbiol Spectr. 2022 Apr 27;10(2):e0149621. doi: 10.1128/spectrum.01496-21. Epub 2022 Mar 21. Microbiol Spectr. 2022. PMID: 35311573 Free PMC article. Review.
At present, most research on CHIKV antigen detection technology tends to combine two or more proteins to avoid the decrease in detection ability caused by antigen mutation. Our results indicate that two or more kinds of CHIKV E antigens combined with LISA detection can imp …
At present, most research on CHIKV antigen detection technology tends to combine two or more proteins to avoid the decrease in detect …
A case of type 2 diabetes mellitus complicated with IgG4-related retroperitoneal fibrosis and a literature review.
Ma D, Wei J, He H, Yang W, Mo Z, Wang F. Ma D, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jul 28;49(7):1073-1081. doi: 10.11817/j.issn.1672-7347.2024.240421. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 39788495 Free article. Review. Chinese, English.
Following comprehensive treatment, including blood glucose and blood pressure control, kidney protection, circulation improvement, and the use of prednisone, the patient's condition significantly improved. The retroperitoneal fibrotic mass decreased in …
Following comprehensive treatment, including blood glucose and blood pressure control, kidney protection, circulation i …
Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
Blanchette VS, Kirby MA, Turner C. Blanchette VS, et al. Semin Hematol. 1992 Jul;29(3 Suppl 2):72-82. Semin Hematol. 1992. PMID: 1509297 Review.
Examples of such questions include the following: (1) Can IVIG therapy, administered early in the course of illness in selected children with acute ITP, decrease the incidence of chronic ITP?; (2) Is maintenance, high-dose IVIG therapy a cost-effective method for th …
Examples of such questions include the following: (1) Can IVIG therapy, administered early in the course of illness in selected children wit …
Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT, Atchison WD. Flink MT, et al. J Bioenerg Biomembr. 2003 Dec;35(6):697-718. doi: 10.1023/b:jobb.0000008033.02320.10. J Bioenerg Biomembr. 2003. PMID: 15000529 Review.
LEMS is generally believed to be due to circulating antibodies directed specifically at the Ca2+ channels located at or near the active zone of motor nerve terminals (P/Q-type) and hence involved in the release of ACh. ...Animal models of LEMS can be generated by chroni
LEMS is generally believed to be due to circulating antibodies directed specifically at the Ca2+ channels located at or near the acti …
Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN. Gade JN. J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S33-7. J Manag Care Pharm. 2004. PMID: 15253688 Review.
Over multiple courses of therapy, alefacept-induced reductions in circulating lymphocyte counts were consistent and not cumulative. The incidences of serious adverse events, discontinuations, malignancies, and antialefacept antibodies were low and did not increase with sub …
Over multiple courses of therapy, alefacept-induced reductions in circulating lymphocyte counts were consistent and not cumulative. T …